Last updated on February 2019

Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia


Brief description of study

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML). This AML was relapsed after previous therapy or was refractory to the standard therapy.

Clinical Study Identifier: NCT03516760

Contact Investigators or Research Sites near you

Start Over

Martin Wermke, MD

Universit tsklinikum Dresden
Dresden, Germany
  Connect »

Stefan Klein, PD Dr.

Universit tsmedizin Mannheim
Mannheim, Germany
  Connect »

Jana Hase

Klinikum rechts der Isar
München, Germany
  Connect »

Götz-Ulrich Grigoleit, MD

Universit tsklinikum W rzburg
Würzburg, Germany
  Connect »

Jana Hase

Universit tsklinikum Frankfurt
Frankfurt am Main, Germany
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.